“If you can see the future, you can change it. People say your eyes are the window to your soul, but the eyes are actually the window to your future health,” Toku Eyes Ltd. Founder and CEO Ehsan Vaghefi told BioWorld.
Tarsier Pharma is developing the small molecule TRS as an anti-inflammatory treatment for retinal diseases, with the eye drop formulation TRS-01 in phase III development for noninfectious anterior uveitis and uveitic glaucoma.
Opthea Ltd. has secured nondilutive funding to complete phase III development and commence commercialization of its wet age-related macular degeneration (wet AMD) treatment OPT-302, in a $170 million agreement with Launch Therapeutics, an operating company set up earlier this year by the private equity group Carlyle to manage biotech investments. Under the terms of the deal, Launch will now commit $120 million in three instalments at fixed time points, with an option to invest a further $50 million.
Positive data from Unity Biotechnology Inc.’s phase II study of UBX-1325, a senolytic BCL-XL inhibitor for treating diabetic macular edema, boosted the stock out of the penny range. Shares of the South San Francisco-based company’s stock (NASDAQ:UBX) rose sharply, 54% on Aug. 12, to $1.31 each.
The phase III miss disclosed Aug. 11 by Kubota Pharmaceutical Holdings Co. Ltd. subsidiary Kubota Vision Inc. in Stargardt disease put more eyes on the rare, inherited, juvenile-onset form of macular degeneration, for which nothing is approved.
Alexion Pharmaceuticals has synthesized new macrocycle compounds acting as complement factor B inhibitors reported to be useful for the treatment of age-related macular degeneration, multiple sclerosis, rheumatoid arthritis, retinal degeneration, chronic obstructive pulmonary disease (COPD), paroxysmal nocturnal hemoglobinuria and cardiovascular disorders.
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models.
Tears shed today by patients frustrated by an inability to obtain a diagnosis could speed diagnoses for others in the future. Researchers at Wenzhou Medical University, China, have developed a new nano membrane system, dubbed I-Tears, that harvests and purifies tiny droplets called exosomes from tears, allowing rapid analysis for disease biomarkers.
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models.
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models.
RSS
